Deargen
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Dongwon F&b 60 Mabang-ro, Seocho-gu, Seo...Phone Number
+82 427162100Website
www.deargen.meRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Deargen
Established in December 2016, Deargen (President: Kilsoo Kang) is an AI-based drug discovery and development company. In February 2020, the company released study results on predicting the development of COVID-19 treatments. Candidate compounds for treating COVID-19 predicted by Deargen include remdesivir, which was first approved as an emergency therapy. The company conducts research on and owns core AI technologies in-silico, such as 'prediction of bio-markers', 'selection of disease targets', and 'extraction of candidate substances for new drugs', utilizing techniques of meta analysis of genome big data and its unique AI technologies. Building on these outcomes, the company is developing new drugs in collaboration with multiple pharmaceutical companies and research institutions, demonstrating its outstanding technology capabilities as being named as top awardees at the ILSVRC, a world-prominent deep-learning competition, and Dream Challenge, an international AI-based new drug develoRead more
Deargen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Deargen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Deargen
Check if Deargen has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Deargen has new funding data
Check out if Deargen is spiking on competitors!
Click to see if Deargen had a recent Job posting/layoffs
Product Launch: Get notified when Deargen launches new products
Earning: See what the market has to say on Deargen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Deargen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Deargen as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Deargen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Deargen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Deargen.
Deargen financials insights
Gather financial insights about Deargen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$17M
Deargen Tech Stack
A closer look at the technologies used by Deargen
Most Recent Scoops
Left Company
Executive Move
Deargen has announced that Bonggun Shin, Chief Executive Officer, has left the organization.
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Funding
Deargen News & Media
Sequence Based, AI-Driven Drug Discovery Company, Deargen Raises US$17 Million in SeriesB Financing Round to Accelerate In-House Pipeline
SEOUL, South Korea--(BUSINESS WIRE)-- #AI--AI-powered drug discovery company, Deargen raised US$17million in a Series B financing round. It will be used to accelerate the in-house pipeline.Deargen Annonuces Patent Application for a TNBC Target Novel Drug Candidate Using AI
Using a self-developed AI platform, it takes only 10 weeks from the discovery of the anticancer drug targets to the discovery and synthesis of new compounds. Proven capabilities for NCE compound discovery and design, and the establishment of a R&D center(iDear Center) to continuously...Deargen-FarmHannong, a Co-Development Agreement to Develop AI-Powered Crop Protection Products
SEOUL, South Korea, Aug. 5, 2021 /PRNewswire/ -- Deargen (CEO Kilsoo Kang), an artificial intelligence (AI)-Powered drug discovery and development company, announced on the 5th that it signed a co-development agreement with FarmHannong (CEO Youjin Lee) on the "development of new crop...Deargen Signs Agreement With Sookmyung Women’s University Research & Business Development Foundation for Licensing ‘NASH Biomarker’ Technologies
SEOUL, South Korea--(BUSINESS WIRE)-- #AI--Deargen signed an agreement with Sookmyung Women’s University Research & Business Development Foundation for licensing ‘NASH Biomarker’ technologies.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Deargen
Sign Up For FreeTo access detailed company insights
Established in December 2016, Deargen (President: Kilsoo Kang) is an AI-based drug discovery and development company. In February 2020, the company released study results on predicting the development of COVID-19 treatments. Candidate compounds for treating COVID-19 predicted by Deargen include remdesivir, which was first approved as an emergency t... Read More
